SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6% - Still a Buy?Market Beat·Jul 16 at 01:00 AMSABS-1.96%STT+0.97%
Breakthrough T1D awards grant to support UF-led PRISE-hATG study of SAB Bio’s SAB-142 in stage 3 type 1 diabetesPUBT·Jul 7 at 07:06 AMSABS-1.96%
SAB Biotherapeutics shareholders elect four Class II directors at annual meetingPUBT·Jun 18 at 03:36 PMSABS-1.96%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Jun 15 at 12:05 PMCYPH-4.01%GNPX+5.21%
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga_article·Jun 15 at 08:55 AMDDOG+0.89%PDM+2.30%
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesdaybenzinga_article·May 20 at 07:53 AMQUIK-4.64%SABS-1.96%
Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)Tip Ranks·May 12 at 10:55 PMSABS-1.96%
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Callbenzinga_article·May 12 at 07:59 AMSABS-1.96%ARKG-0.86%
SAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsUnusual Whales·May 12 at 06:31 AMSABS-1.96%LABU-0.61%
SAB Biotherapeutics (NASDAQ:SABS) Given Buy Rating at Rodman & RenshawMarket Beat·May 11 at 07:23 AMSABS-1.96%XBI-0.22%
